CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will present at two upcoming healthcare investor conferences.
Conference Presentation Details:
Event: SVB Leerink 8th Annual Global Healthcare Conference
Date/Time: Thursday, February 28, 2019 at 3:00 p.m. ET
Location: New York, NY
Event: Cowen & Co. 39th Annual Healthcare Conference
Date/Time: Monday, March 11, 2019 at 1:30 p.m. ET
Location: Boston, MA
A live webcast for the SVB Leerink and Cowen & Co. conference presentations may be accessed on the Investors/Media page of the Company's website at www.acceleronpharma.com. A replay of each webcast will be available approximately two hours after the event on the Acceleron website.
Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.